Géoméga reçoit 1,235
Géoméga reçoit 1,235 M $ de l'exercice de bons de souscription et d'autres instruments
May 10, 2022 07:10 ET | Ressources Géoméga Inc.
Position financière à son meilleur pour générer des investissements records dans les applications de R&D commercialesPlus de 5,1 M $ en trésorerie et équivalents de trésorerieFacilité d'emprunt de...
geomega.png
Geomega Receives $1.235M from Exercise of Warrants and Other Instruments
May 10, 2022 07:10 ET | Geomega Resources Inc.
Strongest ever financial position to drive record investments in commercial R&D applicationsOver $5.1M in cash and cash equivalents$3M interest-free debt facility fully available from IQ for REE...
July 30, 2021 - ROSEN LOGO.jpg
GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages Aurinia Pharmaceuticals Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – AUPH
April 19, 2022 15:15 ET | The Rosen Law Firm PA
NEW YORK, April 19, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of...
roi-pr-343-193.png
BTCS Retires Convertible Note Early, Eliminates Potential Equity Dilution
September 27, 2021 09:21 ET | BTCS Inc.
Silver Spring, MD, Sept. 27, 2021 (GLOBE NEWSWIRE) -- BTCS Inc. (Nasdaq: BTCS) (“BTCS” or the “Company”), a blockchain technology focused company, is pleased to announce that the Company has paid...
2020 Half-year resul
2020 Half-year results: Stronger financial position and research programs moving forward despite the international context
October 01, 2020 12:30 ET | Deinove
2020 Half-year results: Stronger financial position and research programs moving forward despite the international context Clinical program for the antibiotic candidate DNV3837 continues, with the...
logo.png
Corbus Pharmaceuticals Reports 2019 Third Quarter Financial Results and Provides Clinical and Corporate Updates
November 07, 2019 07:05 ET | Corbus Pharmaceuticals Holdings, Inc.
Phase 3 “RESOLVE-1” study of lenabasum for treatment of systemic sclerosis on track for topline results in summer of 2020Systemic sclerosis is a rare autoimmune disease affecting ~200,000 people in...
Logo.png
Update Announcement regarding fundraising and financial position
February 18, 2019 12:00 ET | Gate Ventures Plc
Gate Ventures PLCUpdate Announcement regarding fundraising and financial positionISIN Number: GB00BYX2WP92TICKER: GATEGate Ventures PLCPress ReleaseFebruary 18, 2019 Gate Ventures PLC ("Gate...